Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Wesana Health Hldgs Inc
(OP:
WSNAF
)
0.0111
+0.0028 (+33.73%)
Streaming Delayed Price
Updated: 2:38 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Wesana Health Hldgs Inc
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...
Via
Benzinga
Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
June 12, 2023
Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a...
Via
Benzinga
Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries
June 05, 2023
In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they...
Via
Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
April 13, 2023
“Investing in real estate can help expand experiential medicines like ketamine and MDMA for treating PTSD and build infrastructure for upcoming FDA-approved therapies,” said Daniel Carcillo, founder...
Via
Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
April 03, 2023
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey.
Via
Benzinga
High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis
March 29, 2023
As part of the recent so-called “psychedelics renaissance,” numerous celebrities, global
Via
Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
March 27, 2023
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Via
Benzinga
Lucy Scientific Shares Trading Higher On Asset Purchase Agreement Of Psychedelic Assets From Wesana Health
March 21, 2023
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) has entered into a definitive asset purchase agreement with Wesana Health Holdings Inc. (OTCQB: WSNAF).
Via
Benzinga
NGOs Raise Money To Help Stem Opioid Addiction With Psychedelics Program
October 19, 2022
The 100 Million Ways Foundation (100MW), a not-for-profit organization focused on harm reduction and improving quality of life of those with opioid use disorders, pulled in nearly $100,000 in...
Via
Benzinga
Wesana Sells Clinic Management Services Organization To Strengthen Assets
September 02, 2022
Life sciences company Wesana Health (OTCQB: WSNAF) has completed the sale of its indirect, wholly-owned subsidiary Advanced Psychiatric Management LLC for a total of $2,100,000.
Via
Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
August 30, 2022
Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and
Via
Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
April 25, 2022
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...
Via
Benzinga
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
April 25, 2022
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...
Via
Benzinga
Daniel Carcillo Explains How Wesana Health Is Using Psychedelics To Treat Traumatic Brain Injury
April 20, 2022
Daniel Carcillo is co-founder and CEO of Wesana Health (OTC: WSNAF), a data-driven life sciences company pioneering clinical therapies and drug development through the FDA pathway.
Via
Benzinga
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
April 19, 2022
Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be...
Via
Benzinga
Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD
March 14, 2022
Wesana Health Holdings Inc. (OTCQB: WSNAF) (CSE:WESA) have received a full written response from the Food and Drug ...
Via
Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:
Via
Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.
Via
Benzinga
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
November 04, 2021
Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100. Beck&rsq...
Via
Benzinga
Topics
Death
Exposures
Death
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
September 20, 2021
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares
Via
Benzinga
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
September 14, 2021
Wesana Health (CSE:WESA) (OTCQB:
Via
Benzinga
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M
August 16, 2021
Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ:
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.